cesium iodide

• 分子结构分类: 无机化合物 - 混合金属/非金属化合物 - 碱金属盐
• 英文名称: cesium iodide
• 英文别名: cesium;iodide
• 化学式: CsI
• 分子量: 259.81
• InChiKey: XQPRBTXUXXVTKB-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -5.99
• 重原子数：
  2
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

ADMET

毒理性

• 副作用

皮肤致敏剂 - 一种可以诱导皮肤产生过敏反应的制剂。

Skin Sensitizer - An agent that can induce an allergic reaction in the skin.

来源:Haz-Map, Information on Hazardous Chemicals and Occupational Diseases

反应信息

• 作为反应物：
  描述：

  cesium iodide 生成 cesium;triiodide
  参考文献：
  名称：

  STEPIN, B. D.;TSVETKOV, A. A.;MARGUDIS, V. B.;SAVELEVA, M. V.

  摘要：

  DOI：
• 作为产物：
  描述：

  cesium hydroxide 生成 cesium iodide
  参考文献：
  名称：

  TAKAXASI, TOSIO;KANDZAN, MUNEHO;ONO, MITSUO

  摘要：

  DOI：
• 作为试剂：
  描述：

  苯酚 、 Dicaesio carbonate 、 2-溴-7-甲氧基-3,4-二氢萘-1(2H)-酮 在 cesium iodide silica gel 、 ether-hexane 作用下， 以 丙酮 为溶剂， 反应 18.67h， 以to give 5.14 g (61%) of present title product as an oil的产率得到3,4-Dihydro-7-methoxy-2-phenoxy-1(2H)-naphthalenone
  参考文献：
  名称：

  Substituted tetralins, chromans and related compounds in the treatment

  摘要：

  取代四氢萘、环己基甲基萘和相关化合物，通过抑制5-脂氧化酶酶和/或阻断白三烯受体，在哺乳动物中预防或治疗哮喘、关节炎、银屑病、溃疡、心肌梗死和相关疾病状态，其制药组合物，治疗方法，以及在其合成中有用的中间体。

  公开号：

  US05998451A1

文献信息

• Octadecylamine‐Functionalized Single‐Walled Carbon Nanotubes for Facilitating the Formation of a Monolithic Perovskite Layer and Stable Solar Cells
  作者：Vincent Tiing Tiong、Ngoc Duy Pham、Teng Wang、Tianxiang Zhu、Xinluo Zhao、Yaohong Zhang、Qing Shen、John Bell、Linhua Hu、Songyuan Dai、Hongxia Wang

  DOI：10.1002/adfm.201705545

  日期：2018.3

  approach is developed to synthesize perovskite films consisting of monolithic‐like grains with micrometer size through in situ deposition of octadecylamine functionalized single‐walled carbon nanotubes (ODA‐SWCNTs) onto the surface of the perovskite layer. The ODA‐SWCNTs form a capping layer that controls the evaporation rate of organic solvents in the perovskite film during the postthermal treatment

  由于其优异的光学和电子性能，有机-无机卤化铅钙钛矿具有广阔的应用前景。为了获得高性能的钙钛矿太阳能电池，需要使用具有大晶粒的钙钛矿光吸收层，以便在设备运行期间最大程度地减少晶界和复合。本文中，开发了一种简单而有效的方法，通过将十八烷基胺官能化的单壁碳纳米管（ODA-SWCNT）原位沉积在钙钛矿层的表面上来合成具有微米级尺寸的整体样晶粒的钙钛矿膜。ODA-SWCNT形成覆盖层，该覆盖层控制后热处理过程中钙钛矿膜中有机溶剂的蒸发速率。这种有利的形态反过来大大增强了钙钛矿型太阳能电池的短路电流密度，并几乎完全消除了滞后现象。使用（FA0.83 MA 0.17）0.95 Cs 0.05 Pb（I 0.83 Br 0.17）3作为光吸收剂。此外，具有ODA-SWCNT的钙钛矿太阳能电池表现出非凡的稳定性，在高湿度（60-90％）的环境下经过45天的稳定性测试后，其性能保持率高达80％。这项工作为钙钛
• Vanilloid receptor ligands and their use in treatments
  申请人：Norman H. Mark

  公开号：US20060089360A1

  公开（公告）日：2006-04-27

  Substituted nitrogen-containing heterocycles and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders.

  含有替代氮杂环的化合物及其组合物，用于治疗急性、炎症性和神经性疼痛、牙痛、普通头痛、偏头痛、群集性头痛、混合血管性和非血管性综合症、紧张性头痛、一般炎症、关节炎、风湿性疾病、骨关节炎、炎症性肠病、炎症性眼疾、炎症性或不稳定膀胱疾病、牛皮癣、带有炎症成分的皮肤问题、慢性炎症状况、炎症性疼痛和相关的高敏性和痛觉过敏、神经性疼痛和相关的高敏性和痛觉过敏、糖尿病性神经病疼痛、烧伤后疼痛、交感神经维持性疼痛、感觉缺失综合症、哮喘、上皮组织损伤或功能障碍、单纯疱疹、呼吸、泌尿、消化或血管区域的内脏运动障碍、伤口、烧伤、过敏性皮肤反应、瘙痒、白癜风、一般胃肠道疾病、胃溃疡、十二指肠溃疡、腹泻、坏死剂引起的胃病变、毛发生长、血管运动或过敏性鼻炎、支气管疾病或膀胱疾病。
• High-molecular weight, silicon-containing polymers and methods for the
  申请人：The Regents of the University of California

  公开号：US05229481A1

  公开（公告）日：1993-07-20

  Polymer materials are described, which are formed by polymerization of monomer mixtures containing at least one compound of the formula I (RH.sub.2 Si).sub.x A (I) wherein R is selected from the group consisting of hydrogen, unsubstituted alkyl, substituted alkyl, unsubstituted aryl and substituted aryl; A is a polyvalent moiety; and x is 2-4. Methods for preparation of polymers derived from monomer mixtures consisting essentially of polyvalent polysilanes, as well as mixtures of polysilanes with monovalent monosilanes, are also described.

  本文介绍了由单体混合物聚合而成的聚合物材料，其中单体混合物包含至少一种化合物I（RH.sub.2 Si）.sub.x A（I），其中R选自氢、未取代烷基、取代烷基、未取代芳基和取代芳基组成的群体；A是多价基团；x为2-4。本文还介绍了由多价聚硅烷和单价单硅烷混合物制备的聚合物的制备方法。
• Isoquinolyl substituted hydroxylamine derivatives
  申请人：Ciba-Geigy Corporation

  公开号：US05260316A1

  公开（公告）日：1993-11-09

  The compounds of the formula ##STR1## wherein R represents hydrogen, lower alkyl, aryl, biaryl, C.sub.3 -C.sub.7 -cycloalkyl, aryl-lower alkyl, aryl-lower alkenyl, aryl-lower alkynyl, aryloxy-lower alkyl, arylthio-lower alkyl; C.sub.3 -C.sub.7 -cycloalkyl-lower alkyl, biaryl-lower alkyl, aryl-C.sub.3 -C.sub.7 -cycloalkyl, aryl-C.sub.3 -C.sub.7 -cycloalkyl-lower alkyl or aryloxy-aryl-lower alkyl; and aryl represents carbocyclic or heterocyclic aryl; Z represents C.sub.1 -C.sub.3 -alkylene or vinylene, each unsubstituted or substituted by lower alkyl; Y represents SO.sub.2 or CO; A represents O, S, or a direct bond; B represents lower alkylene; or B represents lower alkenylene provided that A represents a direct bond; X represents oxygen or sulfur; R.sub.1 represents hydrogen, acyl, lower alkoxycarbonyl, aminocarbonyl, mono or di-lower alkylaminocarbonyl, lower alkenylaminocarbonyl, lower alkynylaminocarbonyl, carbocyclic or heterocyclic aryl-lower alkylaminocarbonyl, carbocyclic or heterocyclic arylaminocarbonyl, C.sub.3 -C.sub.7 -cycloalkylaminocarbonyl or C.sub.3 -C.sub.7 -cycloalkyl-lower alkylaminocarbonyl; R.sub.2 represents lower alkyl, lower alkoxycarbonyl-lower alkyl, C.sub.3 -C.sub.7 -cycloalkyl, carbocyclic or heterocyclic aryl, carbocyclic or heterocyclic aryl-lower alkyl, C.sub.3 -C.sub.7 -cycloalkyl-lower alkyl, amino, mono- or di-lower alkylamino, lower alkenylamino, lower alkynylamino, carbocyclic or heterocyclic aryl-lower alkylamino, carbocyclic or heterocyclic arylamino, C.sub.3 -C.sub.7 -cycloalkylamino, C.sub.3 -C.sub.7 -cycloalkyl-lower alkylamino or lower alkoxycarbonyl-lower alkylamino; R.sub.3 and R.sub.4 independently represent hydrogen or lower alkyl; R.sub.a represents hydrogen, lower alkyl, halo, trifluoromethyl or lower alkoxy; and pharmaceutically acceptable salts thereof; their preparation and use as lipoxygenase inhibitors are described.

  该公式的化合物为##STR1##其中R代表氢，低级烷基，芳基，双芳基，C.sub.3-C.sub.7-环烷基，芳基-低级烷基，芳基-低级烯基，芳基-低级炔基，芳氧基-低级烷基，芳硫基-低级烷基；C.sub.3-C.sub.7-环烷基-低级烷基，双芳基-低级烷基，芳基-C.sub.3-C.sub.7-环烷基，芳基-C.sub.3-C.sub.7-环烷基-低级烷基或芳氧基-芳基-低级烷基；芳基代表碳环芳基或杂环芳基；Z代表C.sub.1-C.sub.3-烷基或乙烯基，每个未取代或取代为低级烷基；Y代表SO.sub.2或CO；A代表O、S或直接键；B代表低级烷基；或B代表低级烯基，前提是A代表直接键；X代表氧或硫；R.sub.1代表氢，酰基，低级烷氧羰基，氨基羰基，单或双低级烷基氨基羰基，低级烯基氨基羰基，低级炔基氨基羰基，碳环芳基或杂环芳基-低级烷基氨基羰基，碳环芳基或杂环芳基氨基羰基，C.sub.3-C.sub.7-环烷基氨基羰基或C.sub.3-C.sub.7-环烷基-低级烷基氨基羰基；R.sub.2代表低级烷基，低级烷氧羰基-低级烷基，C.sub.3-C.sub.7-环烷基，碳环芳基或杂环芳基，碳环芳基或杂环芳基-低级烷基，C.sub.3-C.sub.7-环烷基-低级烷基，氨基，单或双低级烷基氨基，低级烯基氨基，低级炔基氨基，碳环芳基或杂环芳基-低级烷基氨基，碳环芳基或杂环芳基氨基，C.sub.3-C.sub.7-环烷基氨基，C.sub.3-C.sub.7-环烷基-低级烷基氨基或低级烷氧羰基-低级烷基氨基；R.sub.3和R.sub.4独立地代表氢或低级烷基；R.sub.a代表氢，低级烷基，卤素，三氟甲基或低级烷氧基；以及其药学上可接受的盐。该化合物的制备及其作为脂氧合酶抑制剂的用途已被描述。
• Certain aryl or hetero-aryl derivatives of 1-hydroxy-pentane or
  申请人：USV Pharmaceutical Corporation

  公开号：US04567184A1

  公开（公告）日：1986-01-28

  Compounds of the structure ##STR1## and pharmaceutically acceptable salts thereof, wherein R.sub.1 and R.sub.2 are independently hydrogen, alkyl, carboxy, alkylcarboxy, arylcarboxy, alkyl carbalkoxy, alkanoyl, formyl, nitrile, amino, amino alkyl, alkylamine, carboxamide, halo, trihalomethyl, hydroxy, alkoxy, aryloxy, nitro, sulfonyl, sulfonamide, thio, alkylthio, or R.sub.1 and R.sub.2 can be taken together to form a phenyl ring; B is C or N, in which N can be in any position of the ring; X is O, S, NR.sub.4, CH.sub.2 Z, CH.dbd.N, CH.dbd.CH, C.tbd.C, CH.sub.2 ZCH.sub.2, C.dbd.O, C.dbd.CR or WC.dbd.O; Y is CHCH.sub.2, C.dbd.CH, C--CH.sub.2, CHCHR.sub.5, CHC(R.sub.5).sub.2 or CC(R.sub.5).sub.2 ; R.sub.3 is O, OH, OR.sub.4, SH, SR.sub.4, NH, HNR.sub.4 or N(R.sub.4).sub.2 ; and M is an integer from 0 to 10; wherein Z is O, S or NR.sub.4 ; R.sub.4 is H, alkyl or aryl; W is O, S or NR.sub.4 ; and R.sub.5 is H, alkyl or fluoro have antiinflammatory and antiallergic activities.

  结构为##STR1##的化合物及其药学上可接受的盐，其中R.sub.1和R.sub.2独立地为氢、烷基、羧基、烷基羧基、芳基羧基、烷基卡巴酯基、烷酰基、甲酰基、腈基、氨基、氨基烷基、烷基胺、羧酰胺、卤素、三卤甲基、羟基、烷氧基、芳氧基、硝基、磺酰基、磺酰胺、硫醇基、烷基硫醇基，或R.sub.1和R.sub.2可结合形成苯环；B为C或N，其中N可以在环的任何位置；X为O、S、NR.sub.4、CH.sub.2 Z、CH.dbd.N、CH.dbd.CH、C.tbd.C、CH.sub.2 ZCH.sub.2、C.dbd.O、C.dbd.CR或WC.dbd.O；Y为CHCH.sub.2、C.dbd.CH、C--CH.sub.2、CHCHR.sub.5、CHC(R.sub.5).sub.2或CC(R.sub.5).sub.2；R.sub.3为O、OH、OR.sub.4、SH、SR.sub.4、NH、HNR.sub.4或N(R.sub.4).sub.2；M为0到10的整数；其中Z为O、S或NR.sub.4；R.sub.4为H、烷基或芳基；W为O、S或NR.sub.4；R.sub.5为H、烷基或氟代基具有抗炎和抗过敏活性。

表征谱图